Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [3529]

ECC 2013: Longest follow-up of largest number of melanoma patients treated with ipilimumab shows some survive up to ten years

ECC 2013: Longest follow-up of largest number of melanoma patients treated with ipilimumab shows some survive up...

ECC 2013: Anti-cancer drug T-DM1 benefits women with advanced breast cancer who have failed several previous treatments: results from TH3RESA trial

ECC 2013: Anti-cancer drug T-DM1 benefits women with advanced breast cancer who have failed several previous...

ECC 2013: Promising results for new antibody drug in non-small cell lung cancer

ECC 2013: Promising results for new antibody drug in non-small cell lung cancer

Phase III START2 trial for tecemotide in stage III non-small cell lung cancer

Phase III START2 trial for tecemotide in stage III non-small cell lung cancer

New targets for melanoma immunotherapy identified

New targets for melanoma immunotherapy identified

Preferential glucose uptake by brain tumour initiating cells

Preferential glucose uptake by brain tumour initiating cells

Mutations in MEF2B lead to deregulation of BCL6 in diffuse large B cell lymphoma

Mutations in MEF2B lead to deregulation of BCL6 in diffuse large B cell lymphoma

Drug used for blood cancers may stop spread of breast cancer cells

Drug used for blood cancers may stop spread of breast cancer cells

Immune system molecule promotes tumour resistance to anti-angiogenic therapy

Immune system molecule promotes tumour resistance to anti-angiogenic therapy

Mechanism offers promising new approach for harnessing the immune system to fight cancer

Mechanism offers promising new approach for harnessing the immune system to fight cancer

More from ecancer